Used in the treatment of nausea and vomiting and vertigo in Ménière’s disease. Administered orally, intramuscularly or intravenously. Since the last update we have not found published data on its excretion in breast milk. It has a weak antimuscarinic action that could have negative effects on milk production in the first weeks postpartum. There is very little literature on this drug and it is sold in very few countries. It can cause severe symptoms at high doses (Yang 1998, JAMA 1968). Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity. If used during breastfeeding, a minimum effective dose is recommended for a limited time, monitoring for signs of irritability or drowsiness in the infant.